retatrutide lilly Eli Lilly's sets new record for weight loss in obesity space Eli Lilly 2023: Crossover appeal

But fair comparison requires acknowledging the differences in trial design, duration, and population that make direct head-to-head claims imprecise

Martins, Gonzalo Barquero, Rodrigo N

Developing drugs that can activate central GLP-1 pathways effectively and for longer durations and ensuring they cross the bloodbrain barrier remains a major challenge

Staying at a lower dose might be the right move if: You are still experiencing good appetite suppression

Fast-forward a few millennia, and here we are in the 21st century, where a simple injection might do what years of meditation couldnt: dial down the dopamine urge on everything, from donuts to dalliances